NASDAQ:NLTX

Neoleukin Therapeutics Stock Forecast, Price & News

$13.62

+0.28 (+2.10 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$12.90

Now: $13.62▼

$13.66

50-Day Range

$10.77

MA: $13.33▼

$15.78

52-Week Range

$5.81

Now: $13.62▼

$18.13

Volume178,084 shs

Average Volume358,943 shs

Market Capitalization$571.15 million

P/E RatioN/A

Dividend YieldN/A

Beta1.09

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Overall MarketRank^™

1.35 out of 5 stars

Medical Sector

607th out of 1,922 stocks

Pharmaceutical Preparations Industry

308th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
Neoleukin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.75, Neoleukin Therapeutics has a forecasted upside of 59.7% from its current price of $13.62.
Amount of Analyst Coverage
Neoleukin Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.6 Community Rank

Outperform Votes
Neoleukin Therapeutics has received 41 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Neoleukin Therapeutics has received 84 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Neoleukin Therapeutics has received 67.20% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Neoleukin Therapeutics and other stocks. Vote “Outperform” if you believe NLTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NLTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Neoleukin Therapeutics does not currently pay a dividend.
Dividend Growth
Neoleukin Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neoleukin Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.10% of the stock of Neoleukin Therapeutics is held by insiders.
Percentage Held by Institutions
65.70% of the stock of Neoleukin Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Neoleukin Therapeutics are expected to decrease in the coming year, from ($0.76) to ($1.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neoleukin Therapeutics is -20.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neoleukin Therapeutics is -20.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neoleukin Therapeutics has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NLTX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.neoleukin.com

Phone206-732-2133

Employees65

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio20.88

Quick Ratio20.88

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$25 million

Price / Sales22.85

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.91 per share

Price / Book4.68

Profitability

EPS (Most Recent Fiscal Year)($0.75)

Net Income$-69,440,000.00

Net MarginsN/A

Return on Equity-24.06%

Return on Assets-21.92%

Miscellaneous

Outstanding Shares41,935,000

Market Cap$571.15 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$13.62

+0.28 (+2.10 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NLTX News and Ratings via Email

Sign-up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions

How has Neoleukin Therapeutics' stock price been impacted by COVID-19?

Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NLTX shares have increased by 71.1% and is now trading at $13.62.
View which stocks have been most impacted by COVID-19.

Is Neoleukin Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neoleukin Therapeutics stock.
View analyst ratings for Neoleukin Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Neoleukin Therapeutics?

Wall Street analysts have given Neoleukin Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neoleukin Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Neoleukin Therapeutics' next earnings date?

Neoleukin Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Neoleukin Therapeutics.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its quarterly earnings data on Monday, November, 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03.
View Neoleukin Therapeutics' earnings history.

What price target have analysts set for NLTX?

8 analysts have issued twelve-month target prices for Neoleukin Therapeutics' shares. Their forecasts range from $18.00 to $30.00. On average, they anticipate Neoleukin Therapeutics' share price to reach $21.75 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts' price targets for Neoleukin Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Neoleukin Therapeutics' key competitors?

Some companies that are related to Neoleukin Therapeutics include Seres Therapeutics (MCRB), Stoke Therapeutics (STOK), Zymeworks (ZYME), Praxis Precision Medicines (PRAX), Harmony Biosciences (HRMY), Shattuck Labs (STTK), Viela Bio (VIE), Prestige Consumer Healthcare (PBH), Kura Oncology (KURA), Dicerna Pharmaceuticals (DRNA), NGM Biopharmaceuticals (NGM), PMV Pharmaceuticals (PMVP), Revance Therapeutics (RVNC), Myovant Sciences (MYOV) and Madrigal Pharmaceuticals (MDGL).
View all of NLTX's competitors.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), Raytheon Technologies (RTX), Honeywell International (HON), The Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and The Home Depot (HD).

Who are Neoleukin Therapeutics' key executives?

Neoleukin Therapeutics' management team includes the following people:

Dr. Jonathan G. Drachman, CEO, Pres & Director (Age 58, Pay $585.81k)
Mr. Kamran Alam, Sr. Strategic Advisor (Age 46, Pay $1.2M)
Dr. David Baker, Co-founder & Member of Scientific Advisory Board
Mr. Robert Ho, CFO & Sec. (Age 44)
Ms. Holly K. Vance, Gen. Counsel
Dr. Carl Walkey, VP of Corp. Devel.
Ms. Samantha Willing, VP of People
Dr. Daniel-Adriano Silva Manzano, VP & Head of Research
Mr. Umut Ulge, VP of Clinical Devel.

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Clarius Group LLC (0.06%) and Janney Montgomery Scott LLC (0.02%). Company insiders that own Neoleukin Therapeutics stock include Bros Advisors Lp Baker, Jonathan G Drachman and Redmile Group, Llc.
View institutional ownership trends for Neoleukin Therapeutics.

Which institutional investors are buying Neoleukin Therapeutics stock?

NLTX stock was acquired by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC, and Clarius Group LLC. Company insiders that have bought Neoleukin Therapeutics stock in the last two years include Bros Advisors Lp Baker, Jonathan G Drachman, and Redmile Group, Llc.
View insider buying and selling activity for Neoleukin Therapeutics or or view top insider-buying stocks.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $13.62.

How big of a company is Neoleukin Therapeutics?

Neoleukin Therapeutics has a market capitalization of $571.15 million and generates $25 million in revenue each year. The company earns $-69,440,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Neoleukin Therapeutics employs 65 workers across the globe.

What is Neoleukin Therapeutics' official website?

The official website for Neoleukin Therapeutics is www.neoleukin.com.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The company can be reached via phone at 206-732-2133 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here